Ken Griffin Ani Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2025 May 15, 2025	SELL	$53.93 - $68.36 $75,502 - $95,704	-1,400 Reduced 41.18%	2,000 $133,000
Q4 2024 Feb 14, 2025	SELL	$53.35 - $61.74 $442,805 - $512,442	-8,300 Reduced 70.94%	3,400 $187,000
Q3 2024 Nov 14, 2024	SELL	$54.33 - $65.72 $38,031 - $46,004	-700 Reduced 5.65%	11,700 $698,000
Q2 2024 Aug 14, 2024	BUY	$58.53 - $68.82 $99,501 - $116,993	1,700 Added 15.89%	12,400 $789,000
Q1 2024 May 15, 2024	SELL	$54.2 - $69.69 $113,820 - $146,349	-2,100 Reduced 16.41%	10,700 $739,000
Q4 2023 Feb 14, 2024	BUY	$48.72 - $65.43 $126,672 - $170,118	2,600 Added 25.49%	12,800 $705,000
Q3 2023 Nov 14, 2023	BUY	$50.28 - $64.61 $40,224 - $51,688	800 Added 8.51%	10,200 $592,000
Q2 2023 Aug 14, 2023	BUY	$37.29 - $53.83 $37,290 - $53,830	1,000 Added 11.9%	9,400 $506,000
Q1 2023 May 15, 2023	BUY	$37.61 - $45.72 $214,377 - $260,604	5,700 Added 211.11%	8,400 $333,000
Q4 2022 Feb 14, 2023	BUY	$31.9 - $41.95 $86,130 - $113,265	2,700 New	2,700 $108,000

241

20.2M

19.9K

12.8K

Ticker ANIP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 17,426,000
Market Cap $1.54B
Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose produc...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.